Propagermanium Induces NK Cell Maturation and Tends to Prolong Overall Survival of Patients With Refractory Cancer.

El propagermanio induce la maduración de las células NK y tiende a prolongar la supervivencia global en pacientes con cáncer refractario.

Clicks: 556
ID: 43770
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #1 of 31 articles by views in Anticancer research

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Propagermanium (PG) inhibits the CCL2/CCR2 axis, and has been shown to function as an immune modulator. This study investigated its anti-tumor mechanism in patients with refractory cancers.Five healthy volunteers and 23 patients with refractory oral (n=8) or gastric (n=15) cancer received PG (30 mg/day). We performed flow cytometry (FCM) of peripheral blood mononuclear cells and in vitro killing assays.FCM revealed that CD16/CD56 NK cells (i.e., mature, cytolytic subset) increased, and the apoptosis induction rate of cancer cells increased after PG administration. Among gastric cancer patients, median OS was 172.0 days. Two patients showed complete remission of lung or liver metastasis. Survival of patients with oral cancer also tended to be prolonged.PG induces NK cell maturation, and may potentiate anti-tumor activity.
El propagermanio (PG) inhibe el eje CCL2/CCR2 y ha demostrado actuar como un inmunomodulador. Este estudio investigó su mecanismo antitumoral en pacientes con cánceres refractarios. Cinco voluntarios sanos y 23 pacientes con cáncer oral (n=8) o gástrico (n=15) refractario recibieron PG (30 mg/día). Se realizó citometría de flujo (FCM) de células mononucleares de sangre periférica y ensayos de citotoxicidad *in vitro*. La FCM reveló que las células NK CD16/CD56 (es decir, la subpoblación citolítica madura) aumentaron, y la tasa de inducción de apoptosis de las células cancerosas se incrementó tras la administración de PG. Entre los pacientes con cáncer gástrico, la mediana de SG fue de 172,0 días. Dos pacientes presentaron remisión completa de las metástasis pulmonares o hepáticas. La supervivencia de los pacientes con cáncer oral también tendió a prolongarse. El PG induce la maduración de las células NK y puede potenciar la actividad antitumoral.
Reference Key
kikuchi2019propagermaniumanticancer Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kikuchi, Shojiro;Noguchi, Kazuma;Wakai, Keiko;Hamazaki, Yoko;Tozawa, Katsuyuki;Jomori, Takahito;Sasako, Mitsuru;Miwa, Hiroto;
Journal Anticancer research
Year 2019
DOI
10.21873/anticanres.13651
URL
Keywords
maturation oral cancer gastric cancer nk cells propagermanium

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.